Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors
Status:
Unknown status
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2, open-label, monocentric, dose-escalation study of lenalidomide in
combination with cetuximab in subjects with solid tumors. The primary objective is to
establish the maximum tolerated dose (MTD) of lenalidomide in combination with cetuximab in
patients with solid tumors including colorectal cancer (CRC), squamous cell carcinoma of the
head and neck (SCCHN) and non-small cell lung cancer (NSCLC).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Medical University Innsbruck
Collaborators:
Celgene Corporation Innsbruck - Tyrolean Working Group of Experimental Oncology (TEXO)